3B Blackbio

Why is 3B Blackbio DX Ltd falling/rising?

As of 31-Aug, 3B Blackbio DX Ltd's stock price is 1,446.15, reflecting a 0.51% increase, driven by strong recent performance and heightened investor interest. The stock has gained 14.19% over the past week and is trading above its moving averages, indicating a robust upward trend.

As of 31-Aug, 3B Blackbio DX Ltd is experiencing a rise in its stock price, currently at 1,446.15, reflecting an increase of 7.4 (0.51%). This upward movement can be attributed to several key factors. The stock has shown strong performance over the past week, with a remarkable gain of 14.19%, significantly outperforming the Sensex, which declined by 0.53% during the same period. Additionally, over the last four days, the stock has consistently gained, accumulating a total return of 14.64%.<BR><BR>Today's trading session has also seen the stock reach an intraday high of Rs 1515, marking a 5.3% increase. The stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 87.1% compared to the 5-day average, suggesting heightened interest and confidence among investors.<BR><BR>Overall, the combination of strong recent performance, positive trading indicators, and increased investor engagement contributes to the rising stock price of 3B Blackbio DX Ltd.

Who are in the management team of 3B Blackbio?

The management team of 3B Blackbio includes D K Dubey (Chairman & Managing Director), N K Dubey (Whole-time Director), Shabbar Husain, Abdul Moin Khan, and Harihar Prasad Thapak (Independent Directors), Mithala Dubey (Non-Executive Director), and Navneet Kaur (Company Secretary & Compliance Officer).

The management team of 3B Blackbio includes the following individuals:<BR><BR>1. D K Dubey - Chairman & Managing Director<BR>2. N K Dubey - Whole-time Director<BR>3. Shabbar Husain - Independent Director<BR>4. Mithala Dubey - Non Executive Director<BR>5. Navneet Kaur - Company Secretary & Compliance Officer<BR>6. Abdul Moin Khan - Independent Director<BR>7. Harihar Prasad Thapak - Independent Director<BR><BR>If you need more specific information about any of these individuals or their roles, feel free to ask!

What does 3B Blackbio do?

3B Blackbio DX Ltd is a micro-cap healthcare services company that focuses on biotechnology, with a recent name change following a merger. As of June 2026, it reported net sales of 33 Cr and a net profit of 10 Cr, with a market cap of INR 1,266 Cr.

Overview: <BR>3B Blackbio DX Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated on May 25, 1972, originally as Kilpest India Limited. It underwent a merger with 3B BlackBio Biotech India Limited, leading to a name change to 3B Blackbio DX Limited in August 2023. The latest reported quarter for net sales and profit is June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 33 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 10 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,266 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Industry P/E: 26 <BR>Dividend Yield: 0.28% <BR>Debt-Equity: -0.30 <BR>Return on Equity: 18.06% <BR>Price to Book: 3.81 <BR><BR>Contact Details: <BR>Address: 7-C Industrial Area, Govindpura Bhopal Madhya Pradesh : 462023 <BR>Tel: 91-0755-2586536/2586537 <BR>Email: kilpestbpl@yahoo.co.in/kilpest@bsnl <BR>Website: http://www.kilpest.com

Who are the peers of the 3B Blackbio?

Peers of 3B Blackbio include Vimta Labs, Krsnaa Diagnostics, Suraksha Diagnostics, Tarsons Products, Laxmi Dental, One Global Services, and Health X Platform. 3B Blackbio has an average management risk, excellent capital structure, and a 1-year return of 0.82%.

Peers: The peers of 3B Blackbio are Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., Tarsons Products, Laxmi Dental, One Global Serv, and Health X Platfor.<BR><BR>Quality Snapshot: Excellent management risk is observed at Suraksha Diagno., Laxmi Dental, One Global Serv, and Health X Platfor, while Average management risk is found at Vimta Labs, Krsnaa Diagnost., Tarsons Products, and 3B Blackbio. Good growth is seen at Suraksha Diagno. and Laxmi Dental, while Average growth is noted at Vimta Labs, Krsnaa Diagnost., Tarsons Products, 3B Blackbio, and One Global Serv. Below Average growth is present at Health X Platfor. Excellent capital structure is attributed to 3B Blackbio, Laxmi Dental, One Global Serv, and Health X Platfor, while Good capital structure is found at Krsnaa Diagnost. and Suraksha Diagno., and Average capital structure is noted at Tarsons Products.<BR><BR>Return Snapshot: One Global Serv has the highest 1-year return at 111.18%, while Krsnaa Diagnost. has the lowest at -29.39%. 3B Blackbio's 1-year return is 0.82%, which is higher than Krsnaa Diagnost. but lower than One Global Serv. Additionally, Laxmi Dental and One Global Serv have negative six-month returns.

How big is 3B Blackbio?

As of 31st August, 3B Blackbio DX Ltd has a market capitalization of 1,266.00 Cr, with recent Net Sales of 153.17 Cr and a Net Profit of 55.53 Cr. Shareholder's Funds are 268.42 Cr and Total Assets are 295.72 Cr as of March 2025.

As of 31st August, 3B Blackbio DX Ltd has a market capitalization of 1,266.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, 3B Blackbio reported Net Sales of 153.17 Cr and a Net Profit of 55.53 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 268.42 Cr and Total Assets of 295.72 Cr.

Which are the latest news on 3B Blackbio?

Should I buy, sell or hold 3B Blackbio DX Ltd?

When is the next results date for 3B Blackbio DX Ltd?

The next results date for 3B Blackbio DX Ltd is 13 August 2026.

The next results date for 3B Blackbio DX Ltd is scheduled for 13 August 2026.

Are 3B Blackbio DX Ltd latest results good or bad?

The latest results for 3B Blackbio DX Ltd are concerning, showing a 57.47% year-on-year revenue growth but a significant quarter-on-quarter decline in net profit by 56.01% and sales by 29.63%, alongside a sharp drop in operating margin and heavy reliance on non-operating income. Overall, these factors suggest potential issues with the company's operational health and future growth prospects.

The latest results for 3B Blackbio DX Ltd present a mixed picture, leaning towards negative. While the company reported a year-on-year revenue growth of 57.47% in Q4 FY26, this was overshadowed by a significant quarter-on-quarter decline in both net profit and sales, with net profit dropping by 56.01% and net sales decreasing by 29.63%. <BR><BR>The operating margin also saw a sharp contraction, falling to 23.96% from 43.14% in the previous quarter, indicating serious cost control issues. Additionally, the company's reliance on other income, which constituted 69.28% of profit before tax, raises concerns about the sustainability of its earnings. <BR><BR>Overall, despite some positive year-on-year growth figures, the deterioration in profitability and margins, along with the heavy dependence on non-operating income, suggest that the results are more concerning than favorable. Investors may view these developments as red flags regarding the company's operational health and future growth prospects.

Is 3B Blackbio technically bullish or bearish?

As of November 17, 2025, 3B Blackbio's trend has shifted to a bearish stance with moderate strength, supported by daily moving averages and Bollinger Bands, despite mixed signals from the MACD across different time frames.

As of 17 November 2025, the technical trend for 3B Blackbio has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this conclusion include the daily moving averages indicating bearish momentum, and the weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, indicating mixed signals across time frames. Overall, the bearish trend is reinforced by the Dow Theory, which is mildly bearish on both weekly and monthly assessments.

How has been the historical performance of 3B Blackbio?

3B Blackbio has shown significant improvement in financial performance, with net sales rising from 61.84 Cr in Mar'23 to 96.47 Cr in Mar'25, and profit after tax increasing from 25.94 Cr to 47.69 Cr during the same period, alongside reduced expenditures and enhanced cash flow. Overall, the company has demonstrated recovery and growth in its financial metrics.

Answer:<BR>The historical performance of 3B Blackbio shows a fluctuating trend in net sales and profitability over the years, with recent improvements noted.<BR><BR>Breakdown:<BR>3B Blackbio's net sales have increased from 61.84 Cr in Mar'23 to 96.47 Cr in Mar'25, following a dip in Mar'22. The total operating income also reflects this upward trend, reaching 96.47 Cr in Mar'25. The company has managed to reduce its total expenditure, which was 76.75 Cr in Mar'21, down to 46.36 Cr in Mar'25. Consequently, the operating profit (PBDIT) has significantly improved, rising from 29.15 Cr in Mar'23 to 50.11 Cr in Mar'25. Profit before tax has also shown a positive trajectory, increasing from 35.31 Cr in Mar'23 to 64.00 Cr in Mar'25, while profit after tax has grown from 25.94 Cr in Mar'23 to 47.69 Cr in Mar'25. The company's total assets have expanded from 214.06 Cr in Mar'23 to 295.72 Cr in Mar'25, indicating a solid growth in financial standing. Cash flow from operating activities has also improved, reaching 43.00 Cr in Mar'25, contributing to a net cash inflow of 6.00 Cr for the same period. Overall, 3B Blackbio has demonstrated a recovery and growth in its financial metrics over the recent years.

Who are the top shareholders of the 3B Blackbio?

The top shareholders of 3B Blackbio include Mithla Dubey with 12.35%, Rashi Daga with 5.3%, and individual investors holding 43.17%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of 3B Blackbio include Mithla Dubey, who holds the highest stake among promoters at 12.35%. The highest public shareholder is Rashi Daga, with a holding of 5.3%. Additionally, individual investors collectively own 43.17% of the company. There are also three foreign institutional investors (FIIs) that hold a combined 2.7%. Notably, there are no pledged promoter holdings and no mutual funds involved in the shareholding.

Is 3B Blackbio overvalued or undervalued?

As of August 11, 2022, 3B Blackbio is considered very expensive and overvalued, with a PE ratio of 29.13, an EV to EBITDA of 26.29, and a PEG ratio of 1.04, despite having a lower PE ratio than Bayer CropScience and P I Industries, but higher than UPL, while its stock has declined 19.90% year-to-date compared to the Sensex's 5.63% gain.

As of 11 August 2022, the valuation grade for 3B Blackbio has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 29.13, an EV to EBITDA of 26.29, and a PEG ratio of 1.04, which suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to its peers, 3B Blackbio's PE ratio is lower than that of Bayer CropScience at 43.48 and P I Industries at 35.59, both of which are also classified as very expensive. However, it is notably higher than UPL, which is rated as attractive with a PE ratio of 38.74. Recent stock performance shows a decline of 19.90% year-to-date, contrasting sharply with the Sensex's gain of 5.63%, reinforcing the notion that the stock may be overvalued in the current market context.

Has 3B Blackbio declared dividend?

Yes, 3B Blackbio DX Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of September 17, 2024. Recent total returns show volatility, with a -16.3% return over the last 6 months but strong performance over longer periods, including a 1282.3% return over the past 5 years.

3B Blackbio DX Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.3%, with a dividend return of 0%, resulting in a total return of -16.3%.<BR><BR>Over the past year, the price return was 78.18%, the dividend return was 0.26%, leading to a total return of 78.44%.<BR><BR>In the 2-year period, the price return was 286.4%, the dividend return was 1.30%, culminating in a total return of 287.7%.<BR><BR>For the 3-year period, the price return was 368.71%, with a dividend return of 2.40%, resulting in a total return of 371.11%.<BR><BR>In the last 4 years, the price return was 278.08%, the dividend return was 2.66%, leading to a total return of 280.74%.<BR><BR>Finally, over the past 5 years, the price return was 1273.79%, with a dividend return of 8.51%, resulting in a total return of 1282.3%.<BR><BR>Overall, while 3B Blackbio DX Ltd has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, contrasting with strong performance over longer periods.